1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (301) 435-9225
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Trends in prostate cancer mortality among black men and white men in the United States†
Article first published online: 3 MAR 2003
DOI: 10.1002/cncr.11212
Published 2003 by the American Cancer Society
Additional Information
How to Cite
Chu, K. C., Tarone, R. E. and Freeman, H. P. (2003), Trends in prostate cancer mortality among black men and white men in the United States. Cancer, 97: 1507–1516. doi: 10.1002/cncr.11212
- †
This article is a US Government work and, as such, is in the public domain in the United States of America.
- ‡
Fax: (301) 435-9225
Publication History
- Issue published online: 3 MAR 2003
- Article first published online: 3 MAR 2003
- Manuscript Accepted: 4 NOV 2002
- Manuscript Revised: 31 OCT 2002
- Manuscript Received: 2 JUL 2002
REFERENCES
- 1, , , , . Rise in prostatic cancer incidence associated with increased use of transurethral resection [see comments]. J Natl Cancer Inst. 1990; 82: 1624–1628.
- 2. Prostate cancer incidence and patient mortality: the effects of screening and early detection. Cancer. 1997; 80: 1857–1863.
- 3, , , , . National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology. 1998; 52: 444–448.
- 4, , , , . Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biomarkers Prev. 1994; 3: 105–111.
- 5, , , . The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995; 273: 548–552.
- 6, , , . Rapid rise and subsequent decline in prostate cancer incidence rates for New Mexico, 1989–1993. Cancer Epidemiol Biomarkers Prev. 1995; 4: 797–800.
- 7, , , , , . The fall in incidence of prostate cancer. On the down side of a prostate specific antigen induced peak in incidence—data from the Utah Cancer Registry [see comments]. Cancer. 1996; 77: 1342–1348.
- 8, , , . Trends in the stage specific incidence of prostate cancer in the Detroit metropolitan area, 1973–1994. Cancer. 1996; 78: 1260–1266.
- 9, , , . Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol. 1997; 158: 1427–1430.
- 10. The results of prostate cancer screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer. 1997; 80: 1835–1844.
- 11, . Prostate cancer incidence and mortality rates among white and black men [see comments]. Epidemiology. 1997; 8: 126–131.
- 12, . Why is the prostate cancer death rate declining in the United States [editorial]? [Published erratum appears in Cancer. 1998; 82: 1802.] , . Cancer. 1998; 82: 249–251.
- 13, , , et al. Cancer surveillance series: interpreting trends in prostate cancer—Part I: evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates. J Natl Cancer Inst. 1999; 91: 1017–1024.
- 14. Interpreting recent trends in prostate cancer incidence and mortality [editorial]. Epidemiology. 1997; 8: 117–120.
- 15, , . Cancer surveillance series: interpreting trends in prostate cancer—Part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999; 91: 1025–1032.
- 16, , . Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000; 11: 167–170.
- 17National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER*Stat version 4.2 [SEER cancer incidence public-use data base, 1973–1999]. Bethesda: National Cancer Institute, 2001.
- 18, , , . A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. J Clin Epidemiol. 1994; 47: 1451–1461.
- 19. Mortality rates by stage-at-diagnosis. Semin Surg Oncol. 1994; 10: 7–10.
- 20U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National Center for Health Statistics. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National Center for Health Statistics, Division of Data Services, 2002. Available at: http://www.cdc.gov/nchs/.
- 21, . Evaluation of birth cohort patterns in population disease rates. Am J Epidemiol. 1996; 143: 85–91.
- 22, . Generalized linear models. London: Chapman and Hall, 1989.
- 23. Re: “Temporal trends in diabetes mortality among American Indians and Hispanics in New Mexico: birth cohort and period effects” [letter]. Am J Epidemiol. 1998; 147: 796–800.
- 24, , , et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis cancer of the prostate treated with definitive radiotherapy: report of Radiation Oncology Group Protocol 85-31. J Clin Oncol. 1997; 15: 1013–1021.
- 25
- 26, , , et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1999; 337: 295–300.
- 27, , , et al. Predicting long term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000; 47: 617–627.
- 28, , , , , . Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999; 341: 1781–1788.
- 29, , , et al. Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced cancer of the prostate. Int J Radiat Oncol Biol Phys. 2001; 50: 1243–1252.
- 30, , , et al. RTOG Protocol 92-02: a Phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced cancer of the prostate. Int J Radiat Oncol Biol Phys. 2000; 48 (Suppl 1): 112.
- 31, , . International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000; 85: 60–67.
- 32, , . International trends in prostate-cancer mortality in the “PSA era.” Int J Cancer. 2001; 92: 893–898.
- 33, , . Birth cohort and calendar period trends in breast cancer mortality in the United States and Canada. J Natl Cancer Inst. 1997; 89: 251–256.
- 34National Cancer Institute of Canada. Canadian cancer statistics 2001. Toronto: National Cancer Institute of Canada, 2001.
- 35, , . Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet. 2000; 355: 1788–1789.
- 36, , . Correction—comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet. 2000; 356: 1278.
- 37. Eradication of a disease: how we cured symptomless prostate cancer. Lancet. 2002; 359: 1341–1342.
- 38, , , . Trends in prostate cancer incidence, mortality and survival in England and Wales, 1971–1998. BJU Int. 2000; 85: 1058–1062.
- 39, , . Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996. Med J Aust. 1998; 169: 21–24.
- 40, , , et al. Prostate cancer mortality after introduction of prostate-specific-antigen mass screening in the federal state of Tyrol, Austria. Urology. 2001; 58: 417–424.
- 41, , , et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2002; 52: 8–22.